Semaglutide Patient Education: Forms and Safety Topics
This educational guide introduces semaglutide terminology, medication forms, and safety topics for discussion with your healthcare provider. For local consultation access and the telehealth process, see our Semaglutide in Sarasota page.
What Is Semaglutide and How Does It Work?
Semaglutide acts as a GLP-1 (Glucagon-Like Peptide-1) receptor agonist. It mimics a hormone the body naturally produces in the intestines. When utilized for weight loss, its primary effects include slowing down gastric emptying (how fast food leaves the stomach) and interacting with receptors in the brain to reduce appetite and increase the feeling of fullness (satiety).
FDA-Approved vs. Compounded
Semaglutide is the active ingredient in several medications. Ozempic, Wegovy, and Rybelsus are FDA-approved brand-name medications. Wegovy specifically holds an FDA-approved indication for chronic weight management.
Important Note on Compounding
During drug shortages, pharmacies may produce compounded semaglutide. While these formulations contain the same active ingredient, compounded semaglutide is clearly NOT FDA-approved. It does not undergo the FDA's strict evaluation for safety, effectiveness, or quality.
Clinical Context and Eligibility
The FDA-approved versions of semaglutide have substantial clinical trial data demonstrating their efficacy in assisting weight management when combined with a reduced-calorie diet and increased physical activity.
Who Is Typically Prescribed Semaglutide?
Providers evaluate patients based on established clinical guidelines. Typically, candidates for medical weight management with GLP-1 medications are adults with an initial body mass index (BMI) of:
- 30 kg/m² or greater (obesity), OR
- 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).
Dosing and Titration
Treatment begins with a low dose that is gradually increased (titrated) over several months. This schedule is designed to minimize gastrointestinal side effects while the body adjusts. You must always follow your provider's specific dosing instructions.
Side Effects and What to Discuss With Your Provider
Before starting semaglutide, you must have an open conversation with a healthcare provider regarding your complete medical history.
Common Side Effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Constipation
- • Abdominal pain or indigestion
- • Fatigue
Serious Risks (Rare)
- • Pancreatitis (inflammation of the pancreas)
- • Gallbladder disease
- • Kidney injury (often linked to dehydration from vomiting/diarrhea)
- • Potential risk of thyroid C-cell tumors
Crucial Safety Warning
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
If you experience severe abdominal pain that will not go away (which may radiate to your back), with or without vomiting, stop using the medication and seek urgent medical care immediately, as these may be symptoms of pancreatitis.
Sources and Attribution
The clinical information provided is adapted from publicly available data from the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), as well as general prescribing information for GLP-1 receptor agonists.
Related Information
Medical Disclaimer: This educational page is not a substitute for a provider evaluation. Prescription of semaglutide requires a comprehensive evaluation by a licensed healthcare provider to determine medical appropriateness.
MEDICAL SOURCES & FURTHER READING
These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.
U.S. Food and Drug Administration
Wegovy prescribing information and Medication Guide (PDF)Semaglutide indications, mechanism, contraindications, thyroid warning, pancreatitis, pregnancy and adverse reactions; this label does not apply to compounded products.
NIH — National Institute of Diabetes and Digestive and Kidney Diseases
Prescription Medications to Treat Overweight & ObesityWeight-management medication eligibility, appetite, lifestyle support and individualized treatment decisions.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight LossLack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.
RESEARCH & REFERENCES
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, et al.; STEP 1 Study Group · New England Journal of Medicine · 2021
Research published in the New England Journal of Medicine reported greater mean weight reduction with semaglutide plus lifestyle intervention than with placebo in the studied population. This was not a study of Sarasota Trim Clinic or compounded medication, and individual results vary.